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Abstract: Small G-proteins are structurally-conserved modules that function as molecular on-off
switches. They function in many different cellular processes with differential specificity determined
by the unique effector-binding surfaces, which undergo conformational changes during the switching
action. These switches are typically standalone monomeric modules that form transient heterodimers
with specific effector proteins in the ‘on’ state, and cycle to back to the monomeric conformation in the
‘off’ state. A new class of small G-proteins called “Roco” was discovered about a decade ago; this class
is distinct from the typical G-proteins in several intriguing ways. Their switch module resides within
a polypeptide chain of a large multi-domain protein, always adjacent to a unique domain called COR,
and its effector kinase often resides within the same polypeptide. As such, the mechanisms of action
of the Roco G-proteins are likely to differ from those of the typical G-proteins. Understanding
these mechanisms is important because aberrant activity in the human Roco protein LRRK2 is
associated with the pathogenesis of Parkinson’s disease. This review provides an update on the
current state of our understanding of the Roco G-proteins and the prospects of targeting them for
therapeutic purposes.
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1. Introduction
The Ras/GTPase superfamily consists of monomeric small GTPases with molecular masses
of 20–30 kDa. Small GTPases act as molecular switches that cycle between the active GTP-bound
and inactive GDP-bound states. The functional cycle is regulated mainly by two different groups
of regulatory proteins: (1) The Guanine nucleotide exchange factors (GEFs), which facilitate GDP
dissociation from the small GTPases and exchanging with GTP leading to the transmission of various
upstream signals; and (2) GTPase-activating proteins (GAPs), which accelerate the speed of the
intrinsic GTP hydrolysis of the GTPase, thereby resulting in the inactivation of the molecular switch.
The Ras/GTPase superfamily perform their cellular function by activating downstream protein kinase
cascades. The Ras signaling pathway is a classic example in the mitogen-activated protein kinase
(MAPK) pathway.
In the past decade, a novel group of Ras/GTPase superfamily has been discovered, which
is called the Ras of complex proteins (Roc). These Roc GTPase exist as a domain within a large
multi-domain protein [1]. Roc was first described in the slim mold Dictyostelium discoideum which
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possesses a complex protein termed GbpC (cGMP binding protein C) [2]. P.J.M. Van Haastert’s
and J.L. Smith’s group identified that GbpC contains a number of different domains, including a
leucine-rich repeats domain (LRR), a Ras domain, MEK kinase domain, a Ras guanine nucleotide
exchange factor N-terminal (RasGEF-N) domain, a DEP domain, a RasGEF domain, a cGMP-binding
domain, a GRAM domain (Glucosyltransferases Rab-like GTPase activators and Myotubularins), and a
second cGMP-binding domain. In this study, the authors proposed that the MEKK activity of GbpC is
intramolecularly regulated by its upstream Ras domain, and that the MEKK activity of GbpC depends
on the cGMP transmitted from the cGMP-binding domains through the RasGEF and Ras domains,
all occurring within the same protein (Figure 1). This Ras domain is unique with respect to the other
canonical Ras-family GTPases, in that both its upstream regulator and its downstream effector kinase
are contained within the same polypeptide chain.
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Figure 1. Schematic depiction of the Roco proteins. A common feature among them is the central Roc-
COR domains, which are flanked by various functional domains. Ank, ankyrin domain; LRR, leucine-
rich repeats; ROC, Ras of complex proteins; COR, C-terminal of Roc; Kinase, kinase domain; WD40, 
WD40-like beta-propeller repeat domain; cNB, cyclic nucleotide binding; DEP, Dishevelled, EGL-10, 
pleckstrin domain; GEF, guanine nucleotide exchange factor; GRAM, glucosyltransferases, Rab-like 
GTPase activators and myotubularins domain; Death, death domain; PTP, protein tyrosine 
phosphatase domain; RhoGEF/RhoGAP, RhoGEF/GAP domain. The red dotted-lines highlight the 
features that differentiate the three groups of Roco proteins. 
Additionally, P.J.M. Van Haastert’s group discovered the region between the Roc and the kinase 
domain COR (C-terminus of Roc), and called proteins consisting of Roc and COR “Roco proteins” for 
their unique structures [1]. The group used the amino acid sequence encompassing the Roc-COR 
tandem domain of GbpC to search for other Roco proteins from various databases. They found Roco 
proteins in prokaryotes, Dictyostelium, plants, and animals, each consisting of a juxtaposition of the 
Roc and the COR domains; there are no proteins containing either Roc or COR domain alone. Based 
on their domain architecture, the identified Roco proteins are categorized into three groups. The 
largest group is found in Dictyostelium and metazoan, which is characterized by the central LRR-Roc-
COR-Kinase tandem domains (Figure 1). In these proteins, the central architecture comprises the Roc-
COR tandem domains, which are always preceded by a leucine-rich repeat domain (LRR) and 
followed by a kinase domain belonging to the MAPKKK subfamily. The N- and C-terminus flanking 
the Roc-COR domain consists of remarkably diverse structures, including WD-40-like beta-propeller 
repeats (WD40 and Kelch motif), and domains which interact with small GTPases (RasGEF, RhoGEF, 
and RhoGAP) [1] (Figure 1). The second group of Roco proteins is characterized by lacking of the 
kinase domain is found in mammals (MASL1), the plant Arabidopsis, and prokaryotes [3] (Figure 1). 
The proteins from this group only contain the central domain architecture, lacking a kinase domain. 
The Death-associated protein kinase (DAPK1) represent the third group of Roco proteins. DAPK1 is 
characterized by its death domain, which is found in proteins with apoptotic functions [4–6]. The 
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Additionally, P.J.M. Van Haastert’s group discovered the region between the Roc and the kinase
domain COR (C-terminus of Roc), and called proteins consisting of Roc and COR “Roco proteins”
for their unique structures [1]. The group used the amino acid sequence encompassing the Roc-COR
tandem domain of GbpC to search for other Roco proteins from various databases. They found Roco
proteins in prokaryotes, Dictyostelium, plants, and animals, each consisting of a juxtaposition of the Roc
and the COR domains; there are no proteins containing either Roc or COR domain alone. Based on their
domain architecture, the identified Roco proteins are categorized into three groups. The largest group
is found in Dictyostelium and metazoan, which is characterized by the central LRR-Roc-COR-Kinase
tandem domains (Figure 1). In these proteins, the central architecture comprises the Roc-COR tandem
domains, which are always preceded by a leucine-rich repeat domain (LRR) and followed by a kinase
domain belonging to the MAPKKK subfamily. The N- and C-ter inus flanking the Roc-COR domain
consists of remarkably diverse structures, including WD-40-like beta-propeller repeats (WD40 and
Kelch motif), and domains which interact with small GTPases (RasGEF, RhoGEF, and RhoGAP) [1]
(Figure 1). The second group of Roco proteins is characterized by lacking of the kinase domain is found
in mammals (MASL1), the plant Arabidopsis, and prokaryotes [3] (Figure 1). The proteins from this
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group only contain the central domain architecture, lacking a kinase domain. The Death-associated
protein kinase (DAPK1) represent the third group of Roco proteins. DAPK1 is characterized by its death
domain, which is found in proteins with apoptotic functions [4–6]. The central domains architecture
of DAPK is followed by the death domain, whereas the kinase domain is located in the N-terminus,
and is the only one that lacks an LRR domain in the group. DAPK1 was first identified in the 1990s [7]
as a serine/threonine kinase that is a positive mediator of programmed cell death induced by IFN-γ.
Although the Roco proteins, such as DAPK1 and a few from Dictyostelium and prokaryotes
described above, have been studied for some time [1,8], they were not widely studied, and the features
of Roc-COR had not been well characterized until two research groups linking mutations in the gene
encoding leucine-rich repeat kinase 2 (LRRK2), a human Roco protein, with autosomal dominant
Parkinson’s disease (PD) in 2004 [9,10]. Since then, there has been intense interest and research activity
in the quest to understand the details of Roco proteins. Due to the association of LRRK2 with both
familial and sporadic PD, it has become the most intensively-studied protein among the Roco family.
Abnormally high kinase activity of LRRK2 is associated with PD pathogenesis; therefore, the majority
of studies have been mainly focused on understanding the role of the kinase activity in relation to
the biological function of LRRK2 and in disease. A unique feature of LRRK2 is that it catalyses two
distinct biochemical activities, phosphotransfer via its kinase domain and GTP hydrolysis via its Roc
domain [11,12]. Although the Roc domains of Roco proteins are annotated as belonging to the small
Ras GTPase superfamily, P.J.M. Van Haastert’s group utilized Cluster Analysis for 21 Roc domains
and 34 other small GTPases to reveal that the Roc domains were clearly distinguished from the other
groups of Ras/GTPase proteins [1,13]. This can explain why the Roc domain of DAPK1 had remained
unidentified for decades, despite having been well-studied since the 1990s [7]. In recent years, there
has been increasing interests in understanding the role of the GTPase activity of Roco proteins in an
effort to understand the pathogenesis mechanisms LRRK2 in PD [8,14]. In this review, we will focus
on discussing the potentially unique mechanism of action of the Roc domain compared to the classic
Ras/GTPase, and the roles of GTPase activity in the functioning of Roco proteins and in disease.
2. Biological Functions of Roco Proteins
The Roco family of proteins have been identified in a wide phylogenetic range, from bacteria
to humans [1]. This family of proteins has drawn intense interest because it has been linked with
human disease. For example, mutations in LRRK2 have been associated with PD [9,10], and DAPK1
has been associated with cancer [6,7]. The diversity of domains flanking either side of the central core
GTPase and kinase domains, including a variety of regulatory and protein-protein interaction domains,
indicate that these proteins have diverse functions, and that the Roc domains appear to serve as the
molecular switches that regulate their activities.
2.1. GbpC and Pats1 in D. Discoideum
Some of the most studied Roco proteins have been found from D. discoideum. Although 11
Roco genes have been identified in D. discoideum so far [1], GbpC and Pats1 (protein associated with
transduction of signal 1) have been the most thoroughly studied. GbpC plays an important role in
chemotaxis in slime mold [15,16], a process that involves the phosphorylation of myosin II and its
assembly in the cytoskeleton, which is regulated by cGMP binding [16]. In addition to the Roc-COR
tandem domain and kinase domain, GbpC has a peculiar C-terminal region that contains a Ras guanine
exchange factor (Ras-GEF) domain, a GRAM domain, and 2 cGMP-binding domains. The binding
of cGMP to GpbC induces an intramolecular activation mechanism by sequentially activating the
Ras-GEF, Roc, and kinase domains [17] (Figure 2). GbpC translocation is induced by cAMP and
depends on its GRAM domain to associate with the cellular membrane and cell cortex [18]. At the
membrane and cell cortex, GbpC would phosphorylate its substrates via its kinase domain, which
in turn is regulated by the upstream signals from Roc [18]. It appears that the Roc domain of GbpC
functions by undergoing a G-protein cycle that is reminiscent of the canonical G-proteins, except that
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the upstream regulator and the downstream effector happen to reside in the same polypeptide chain.
It is still unclear whether or not these interesting findings are inferable to all other Roco family proteins.Int. J. Mol. Sci. 2018, 19, x 4 of 15 
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2.2. Human Roco Proteins: DAPK1, LRRK1/2, MASL1
The four human Roco proteins identified so far comprise DAPK1, LRRK1 (leucine-rich repeats
kinase1), LRRK2 (leucine-rich repeats kinase 2), and MASL1 (malignant fibrous histiocytoma amplified
sequence 1). A common feature among these four proteins is that they all contain a central Roc-COR
domain characteristic of Roco proteins; however, the variety of the different surrounding domains
illustrates the diverse functions of these proteins. The smallest of the group, MASL1, is composed
of only three domains, an LRR domain followed by the Roc-COR tandem domains. It lacks a kinase
domain, thereby leaving GTPase as its sole catalytic activity, indicating that most likely the Roc domain
is the main functional domain to carry out its cellular functions [8,14]. DAPK1 consists of a kinase
domain at the N-terminus followed by an ankyrin repeat (ANK), then the central Roc-COR domain,
which in turn is followed by its death domain (which is a protein-protein interaction mediating domain
that exists in many apoptosis-promoting proteins) [20]. LRRK2 and LRRK1 are closely related in
vertebrates [21]. However, LRRK1 has rarely been reported to be associated with a human disease
except that one family was found to carry LRRK1 mutations linked to the osteosclerotic metaphyseal
dysplasia (OSMD) [22], while LRRK2 has been strongly associated with PD, Alzheimer’s disease (AD),
and immune disorders [23,24]. As such, LRRK2 has been an important potential drug target for PD.
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DAPK1 was first discovered as a protein involved in the process of cell death [7], and it was
subsequently determined to be a positive regulator of both apoptotic and type-II autophagic cell
death [7,25]. DAPK1 might also function as a tumor suppressor by triggering apoptosis. Mutations
leading to a reduced expression of DAPK1 have been associated with inheritable predisposition to
chronic lymphocytic leukemia [26]. Additionally, DAPK1 may also be involved in neuronal cell death,
such as epilepsy and Alzheimer’s disease [27]. The Roc domain negatively regulates DAPK1 activity
through binding GTP to the P-loop motif of its Roc domain. The Roc domain of DAPK1 has also been
implicated in mediating cellular functions through the formation of a DAPK1 homodimer, as well as
by interacting with other Roco family proteins and cytoskeleton, including LRRK2 protein [25,28,29].
The biological function of MASL1 is the least understood among the four human Roco proteins.
MASL1 was originally identified as a novel gene which was amplified from a malignant fibrous
histiocytoma, implying that MASL1 was involved in cell fate and division [30]. Later cellular studies of
MASL1 suggested that it plays a role in the regulation of erythroid differentiation of CD34 (+) cells and
necrotic cell death through the ERK pathway [31]. The Roc domain of MASL1 has been demonstrated to
physically interact with Raf1, which is upstream of ERK signal cascade [31]. Because MASL1 lacks a kinase
domain, its Roc domain acts on extramolecular effectors similar to the classic Ras/small GTPase family.
LRRK1 is closely related to LRRK2, and it was believed that they derived from the same ancient
gene via DNA duplication [32]. Both LRRK1 and LRRK2 are expressed widely in human tissues and
organs, including the brain. Although they share a very similar multi-domains architecture, mutations
in LRRK2 are strongly associated with familial and sporadic PD, whereas mutations in LRRK1 are
found in a family with OSMD [22]. Recent findings from Weirong R. Xing’s group suggest that LRRK1
regulates actin assembly in mature osteoclasts by phosphorylating L-plastin [32,33].
Among the human Roco proteins, LRRK2 has been the most studied. Human genetics has
linked LRRK2 to PD, Crohn’s disease, multibacillary leprosy, and cancer [34]. LRRK2 has been
implicated in a wide range of cellular processes including mitochondrial maintenance, synaptic
vesicle cycling, autophagy, lysosomal biology, cytoskeletal regulation, neurite outgrowth regulation,
and translational control [35,36]. Mice having LRRK2 knocked out showed kidney, lung, and liver
abnormalities, including the accumulation of vesicles within cells and alterations in markers for
autophagy [37,38]. A more recent study showed that alteration in LRRK2 could also result in defective
chaperone-mediated autophagy (CMA) [39]. LRRK2 has been shown to interact with many cytoskeletal
proteins, including β-tubulin [40], actin [41] and moesin [42], thus suggesting that LRRK2 might play a
role in the control of cytoskeletal remodeling and regulating neurite outgrowth [43–45]. An increasing
number of studies are implicating LRRK2 functioning at membranous structures [46,47]. In 2014,
Mark Cookson’s group performed a chip-based LRRK2 interaction screening assay and found a
number of interactors known to be involved in the vesicular recycling process, including Rab7L1, which
is also involved in intracellular protein sorting [48,49]. Further investigation by Dario Alessi’s group
showed that Rab7L1 recruits LRRK2 to the trans-Golgi network, and that this interaction activates the
kinase activity of LRRK2 [50]. Using a phosphoproteomics approach, the same team also identified
a subset of Rab GTPases as potential substrates of LRRK2 [51], then they used systematic proteomic
analysis to identify ten specific Rabs that were endogenously phosphorylated by LRRK2 [52], thereby
identifying a potential role for LRRK2 in ciliogenesis. Subsequently, the same team in collaboration
with Susan Pfeffer’s group showed that LRRK2 blocks primary cilium formation through the Sonic
hedgehog signaling pathway [53].
Taken together, it appears that LRRK2 plays an important role in a number of different cellular
processes involving membranous structures; however, its precise function(s) and mechanism in disease
pathogenesis remain elusive.
3. Biochemical Activity of Roc and Its Regulatory Mechanisms
The typical small G-proteins function as molecular switches by cycling between the GDP-bound
inactive and GTP-bound active conformations. This biochemical cycle is composed of a binary process;
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the GDP-bound inactive state is switched to the activated state upon GTP binding, and reciprocally,
the GTP-bound active state is switched off by the intrinsic GTP hydrolysis activity of G-protein. These
changes are intricately controlled by GEFs, which promote the exchange of GDP with GTP, and by
GAPs, which accelerate the biochemical hydrolysis of GTP. Utilizing this highly-conserved functional
G-protein fold, their different subcellular localization and specific downstream effectors enabled the
small G-proteins to regulate a diverse set of biological processes in the cell. The small G-proteins in
the Roco family of proteins are unique, in that they are intramolecularly-linked with a COR domain,
and their nucleotide exchange process might not require GEFs or GAPs. However, the molecular
details of their mechanism of action remain to be elucidated.
3.1. Roco Proteins are Functional GTPases
G-proteins are characterized by two main functions: guanosine nucleotides (GDP and GTP)
binding and GTP hydrolysis. The guanosine nucleotide-binding property of the Roco proteins has
been widely reported for proteins from prokaryotic to human [25,28,54]. Wouter N. van Egmond
and colleagues used GTP-agarose pull down to assay for the GTP binding ability of D. discoideum
GbpC, and they demonstrated that the nucleotide exchange process of Roc domain of Gbpc was
specifically activated by its C-terminus GbpC-RasGEF domain [17]. Katja Gotthardt and colleagues
quantified the nucleotide binding ability of C. tepidum Roco in vitro by using purified recombinant
Roc-COR domain, which showed that Roco has the low binding affinity for both GDP and GTP (in the
micromolar range) [55]. Guanosine nucleotides binding of the human Roco proteins has been well
studied. Rodrigo Carlessi and colleagues showed that an excess of free GTP could competitively
deplete the pulled-down DAPK1 from GTP-agarose and that the artificial mutation T701N in the
P-loop motif of Roc domain, which would disrupt GTP binding, significantly increasing the kinase
activity of DAPK1 compared to that of the WT [28]. Sybille Dihanich and coworkers measured GTP
binding for MASL1 using GTP-agarose pull-down assay in mammalian cells and showed that GTP
binding was necessary for the complex formation of MASL1 in cells [56]. There is also an abundance
of evidence showing human LRRK1 and LRRK2 binding with GTP and GDP [54,57]. Both LRRK2
full-length and its isolated Roc domain or Roc-COR tandem domain have been reported to selectively
bind to GDP and GTP with similar affinity [12,54,55], and that mutations in the nucleotide-binding
P-loop, such as K1347A or T1348N, resulted in a reduction of GTP/GDP binding [58].
Similarly, the GTP hydrolysis activity of the Roc domains of the Roco proteins has been well
characterized, including DAPK1 [28], LRRK2 [12], and the Chlorobium tepidum Roco [55]. Among them,
LRRK2 has garnered the most attention. Several groups have demonstrated that LRRK2 is able to
hydrolyze GTP using radioactively labeled guanine nucleotide to assess its intrinsic GTPase activity
in vitro [54], and this activity is disrupted when the key residues in the P-loop required for nucleotide
described above are mutated. Truncation constructs consisting of just the Roc domain or the Roc-COR
tandem domain retains LRRK2 GTPase activity; however, the activity is significantly lower than that
of the full-length protein, indicating that the GTPase activity may be intramolecularly modulated
via interaction with other domains (Figure 3) [12,55,59]. Although the mechanism of action of the
Roc G-protein remains unclear, it might be different from that of the typical G-proteins. For example,
LRRK2 carrying the mutation R1398L resulted in a protein that possesses higher GTPase activity,
while the equivalent mutation in Ras would abolish GTPase activity and trap it in a persistently active
form [58,60]. A dual substitution mutant, combining the R1398L with a T1343V, in P-loop has created
an active form of LRRK2 with impaired GTPase activity [58]. These artificial mutations confirm the
GTPase activity of the Roc domain of LRRK2, and suggest that it might function a little differently than
the typical G-proteins.
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over-activate the kinase domain. A set of Parkinson’s disease-associated mutations in the Roc domain 
(R1441G/H/C) also activate LRRK2 kinase activity. 
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3.2. Regulatory Mechanisms of Roc Activity
As mentioned above, the Roc domain of GbpC from D. Discoideum is uniquely regulated by its
RasGEF domain in the same polypeptide chain. A number of studies have set out to identify the
GEFs and GAPs for LRRK2. One of the potential GEFs identified for LRRK2 is ArhGEF, which is a
GEF of CDC42 and Rac1, and its interaction with LRRK2 appears to increase GTPase activity in cells
and mouse brain [61,62]. ArhGEF binding to LRRK2 might be dependent on the phosphorylation
state of LRRK2, which is stimulated by CK1α [63]. Interestingly, ArhGEF can also be phosphorylated
by LRRK2 in vitro [62]; however, it is unclear how ArhGEF affects the kinase activity of LRRK2
and how its phosphorylation of ArhGEF affect the activity of the GEF. It has been shown that the
kinase activity of LRRK2 is toxic in yeast and a genetic screen for suppressors of this toxicity has
found a GAP, GCS1, as a suppressor of LRRK2-induced toxicity [60]. The mammalian homologue
of GCS1, ArfGAP1, has been tested for its interaction with LRRK2 in human cells and in rodent
brains, and in vitro assays showed that ArfGAP1 causes an approximately 2–3 fold acceleration of the
GTPase activity of LRRK2 [64,65]. Surprisingly, ArfGAP1 is found to interact with the N-terminus
and C-terminus portions of LRRK2 rather than at the expected catalytic core region where the Roc
domain resides [64,65]. If ArfGAP1 is indeed a GAP for Roc, then it would indicate that the GAP
activating mechanism of Roc is more complex and different than that of the canonical small GTPases.
Another potential GAP for LRRK2 is RGS2, which was originally identified in C. elegans as a modulator
of LRRK2 [66]. RGS2 is subsequently shown to interact with LRRK2, and in so doing, increases its
GTPase activity leading to a reduction in kinase activity in vitro [66]. It is unclear how ArfGAP1 and
RGS2 both activate GTP hydrolysis of LRRK2 while showing the opposite effect on its kinase activity
and neuronal toxicity. It remains to be determined whether or not ArfGAP1 or RGS2 are authentic
physiological GAPs of LRRK2.
Interestingly, biochemical characterization of the LRRK2 protein reveals that the guanosine
nucleotide affinity is much weaker than that of the canonical small GTPases [12,55]. Generally,
the nucleotide affinity of Ras family of proteins is in the range from picomolar to nanomolar, whereas
the nucleotide affinity of LRRK2 is in the micromolar range. The low affinity or nucleotides would
enable nucleotide exchanges to occur in LRRK2 in the absence of GEFs. There is a precedent for
a GEF- and GAP-independent G-protein activation mechanism. Raphael Gasper and colleagues
classified a group of G proteins that are regulated by dimerization as GADs (G-proteins activated by
nucleotide-dependent dimerization), including the SRP (signal recognition particle), the dynamins,
and the septins [67]. Indeed, LRRK2 has been proposed as a GAD G-protein based on the structural
study of prokaryotic C. tepidum Roco protein model [55]. The basic mechanistic feature that
distinguishes GADs from the typical small G-proteins is that GADs do not require GEFs and GAPs
for nucleotide exchange and GTPase activation, but instead, nucleotide exchange is dependent on
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the local concentration of the nucleotides, and GTPase activation is conferred upon dimerization [67].
The notion that LRRK2 is a GAD G-protein has been inferred from the studies of the C. tepidum Roco.
A Roc-COR contiguous construct of the CtRoco has been crystallized as constitutive homodimer
stabilized by the interactions between the two COR domains. Based on the structure, it was proposed
that the dimerization mediated by the two COR domains would position the Roc domains in close
proximity to each other, thereby exchanging an Arginine residue that would complement and constitute
a productive catalytic site [55]. Katja Gotthardt and colleagues suggested that the structure of the
prokaryotic CtRoc-COR construct has implications for LRRK2, although the key active-site residues
are not conserved [55]. Even so, there is evidence consistent with LRRK2 being a GAD G-protein.
For example, LRRK2 has been reported to predominantly exist as a homodimer in cells [68,69],
its COR domain dimeric interface is the most highly-conserved region among Roco proteins [70],
the isolated COR domains of LRRK2 interact with each other [55,59], and the familial mutations
(R1441C/G/H) disrupt dimerization and reduce GTPase activity [71,72]. However, several lines of
evidence have shown that the isolated Roc domain of LRRK2 is catalytically active in its monomeric
state in solution [12,73], demonstrating that dimerization is not essential for its GTP hydrolysis activity
(which is inconsistent with the GADs model). Of note is that the catalytic arginine residue R543 of
the ortholog C. tepidum Roc-COR does not exist in human LRRK2; therefore, it is still unclear whether
the mechanism of action of CtRoco is the same as that of the human LRRK2. Another observation of
LRRK2 that is inconsistent with the GAD model is that the binding of nucleotides does not regulate
LRRK2 dimerization in cells. On the other hand, the human DAPK1 forms a homodimer in cells
through interactions in the Roc and kinase domain instead of the COR domain.
More recently, Egon Deyaert and colleagues proposed that the GTPase catalytic activity of the C.
tepidum Roco protein is regulated by the conformational changes between dimeric and monomeric
states during the process of GTP turnover [74]. In contrast to the GAD model mentioned above,
the current dimer-monomer cycle model posits that GTP binding induces monomerization, and that
GTP hydrolysis occurs in the monomeric form of the enzyme. LRRK2 has been observed to
cycle between a dimeric kinase-active form and a monomeric kinase-inactive form in vivo [69,75].
The studies demonstrated that stabilization of either the dimeric or monomeric state of LRRK2 led to
decreased GTPase activity [74].
Additionally, emerging evidence has indicated that the intramolecular kinase activity might
reciprocally regulate the GTPase activity [73,76]. For example, autophosphorylation sites mapping of
LRRK2 using mass spectrometry has found that many of these sites are clustered in the Roc domain,
such as T1343, T1348, S1403, T1404, T1410, and T1503 [77–79]. Interestingly, these residues map
primarily to the P-loop motif (which involves in nucleotide binding) and the switch regions (which
mediate GTP binding or GTP hydrolysis) of Roc, suggesting that autophosphorylation at the Roc
domain could potentially affect nucleotide binding and/or GTP hydrolysis. It has been reported that
the phosphorylation of residue T1503 may regulate GTP binding and kinase activity of LRRK2 [11].
Another study showed that the phosphorylation of residues in the Roc domain increases the rate of
GTP hydrolysis [73]. In addition to the intrinsic kinase activity, an extrinsic kinase PKA has also been
shown to phosphorylate residue S1444 of LRRK2, where the phospho-binding protein 14-3-3 has been
shown to dock, and in turn, 14-3-3 binding causes a decrease in the kinase activity of LRRK2 [80].
In addition to the cluster of sites located in the Roc domain mentioned above, autophosphorylation
sites are also found in the region between the ANK domain and LRR domain, including S910, S935,
S955, and S973 [81]. Since the phosphorylation of LRRK2 is a potential regulation mechanism of
LRRK2, then its dephosphorylation might also a play a role. Indeed, several pathogenic mutants
in LRRK2 have been shown to have a reduced phosphorylation level at the above ANK-LRR
inter-domain phosphosites [82]. Moreover, inhibition of LRRK2 also resulted in a reduction of
phosphorylation at these sites, thus lending support to the notion that the phosphorylation and
dephosphorylation of LRRK2 are potentially a regulatory mechanism of LRRK2, as thoroughly
reviewed by Jean-Marc Taymans [83]. Two potential LRRK2 phosphatases have been identified
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in recent years. In 2013, Evy Lobbestael and colleagues showed that the protein phosphatase 1 (PP1)
can effectively dephosphorylate LRRK2 at S910, S935, S955, and S973 [82]. More recently, in 2017,
Panagiotis Athanasopoulos and colleagues identified protein phosphatase 2A (PP2A) as another
potential LRRK2 phosphatase [84]. This study showed that PP2A interacts with the Roc domain of
LRRK2, and that knocking down the activity of PP2A aggravated cellular degeneration induced by a
pathogenic LRRK2 mutant. The mechanisms of how each phosphosite affect the activity of LRRK2
is unknown, but because LRRK2 is a large mutli-domain and dual enzymatic protein, the different
phosphosites might regulate the distinct characteristics. In additional to the conventional effects of
phosphorylation on protein-protein interactions and conformational changes, Jing Zhao and colleagues
reported recently that LRRK2 dephosphorylation could lead to ubiquitination, thus suggesting that
the dephosphorylation of LRRK2 might also regulate its levels in the cell [85].
4. The Mechanism of Roc Transmitting Its Signal Downstream
The typical Ras-family GTPases undergo guanine nucleotide-dependent conformational changes
that alter their interactions with various effectors in the cellular signaling cascades leading to changes
in subcellular localization and/or oligomeric states. However, the Roco-family G-proteins are
contiguously fused with a COR domain, and most of them comprise of an intramolecular kinase
domain, among others. Given this modular arrangement that consists of a G-protein and a potential
effector kinase in the same polypeptide chain, it is tempting to imagine that the Roc domain might
interact with its intramolecular kinase domain in a fashion analogous to that of Ras with the MAP
kinases. Indeed, in slime mold, the activation of the Roc domain of GbpC with GTP stimulates the
activity of its kinase domain, which then goes on phosphorylates its downstream substrates [17,18].
Similar evidence also exists for the human Roco proteins. Daniel Korr and colleagues observed that the
kinase activity of LRRK1 could be stimulated by GTP binding [57], and that this kinase activity, which
modulates osteoclast function, is regulated by cycling between GTP and GDP-bound Roc domain,
which is reminiscent of the canonical Ras-family small GTPases [32,33]. More recently, several lines
of evidence demonstrate that the kinase activity of LRRK2 is also regulated in a GTP-dependent
manner [86–88]. The Roco proteins, lacking an intramolecular kinase domain, appear to transmit
their signals extramolecularly, which is similar to the canonical G-proteins. For example, the Roc
domain of MASL1, which lacks an intrinsic kinase domain, is also activated by GTP-binding; however,
once activated, it regulates the extrinsic kinases in the Raf/MEK/ERK signaling cascade that is
involved in the erythropoiesis. Interestingly, in contrast to LRRK1/2 and MASL1, GTP binding
to the Roc domain of DAPK1 results in the down-regulation of its kinase activity [17,18]. All this
suggests that the mechanisms of action of the Roc G-proteins are more complex than those of typical
small G-proteins; however, the mechanism of nucleotide binding-induced conformational changes
leading to the toggling of the molecular switch observed in the typical G-protein appear to be conserved
in the Roc proteins.
It is still unclear how the nucleotide-dependent conformational changes in the Roc domain
of the Roco proteins result in the activation of their kinase domain. However, several lines of
evidence suggest the involvement of dimerization and/or overall conformational changes leading to
rearrangement of the domains. For example, Rodrigo Carlessi and colleagues revealed that the Roc
domain of DAPK1 mediates its homodimerization as well as its heterodimerization with other kinases,
including LRRK2 and ZIPK (ZIP-kinase); however, the mechanistic significance of the dimerization
event was unclear at the time [28]. They also showed that deletion of the Roc domain resulted in
a more-active DAPK1, indicating that dimerization of the Roc domain is not required for DAPK1
enzyme activity, yet dimerization might be crucial for GTPase activity which directly regulates kinase
activity [28]. In contrast, a number of studies have shown that purified full-length LRRK2 forms
dimers in solution in vitro and cells [68,89,90]. Saurabh Sen and colleagues observed that LRRK2
isolated from different species were only catalytically active in their dimeric form [68]. Nicholas G.
James and colleagues found that the majority of cytoplasmic LRRK2 is monomeric, and that the LRRK2
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oligomers, including dimers, tetramers, or higher-order oligomers, are associated with the plasma
membrane or the intracellular membranous structures [49,91]. Other studies have shown that the
membrane-associated LRRK2 is dimeric and is more catalytically active than the cytosolic monomeric
conformation [69]. As such, it appears that guanine nucleotide-binding drives Roc conformational
changes that, in turn, alter the conformation and/or oligomeric states of the Roco proteins, ultimately
leading to altered protein-protein interactions and/or subcellular localization. However, the defining
feature that distinguishes Roc from all other G-proteins is the juxtaposition of Roc and COR. Roc always
co-exists contiguously with a COR domain, suggesting that they likely function as a unit; however,
how the two domains work together is still a mystery. Understanding the interplay between Roc and
COR is essential for understanding the mechanism of action of this unique class of G-proteins.
5. Conclusions
The Roco family of G-proteins is the most recently characterized and least understood of the
Ras-like small G-protein family. It is a class of G-proteins in which the G-domain functions within
a multi-domain protein and is characteristically conjoined with a COR domain. Understanding
the details of the functioning of the Roco proteins will have important applications. For example,
LRRK2 is currently the most promising drug target for Parkinson’s disease, and it is being intensively
investigated for that purpose. Because the aberrant kinase activity of LRRK2 is associated with
disease pathogenesis, most efforts in drug discovery have been focused on inhibiting its kinase
domain. This has yielded a number of highly specific and potential inhibitors of LRRK2 kinase
activity [92–94]. However, inhibition of LRRK2 kinase activity has led to detrimental side-effects in
animal models [37,38,95,96]. Still, researchers in the field are working to modulate LRRK2 kinase
activity to achieve therapeutic doses and minimize side-effects.
The unique structure comprising of the Roc-COR domains might provide an alternative venue for
therapeutic development. This is an attractive strategy because, in addition to the unique structure that
might offer specific drug binding sites, it is an intrinsic modulator of the kinase domain; thus, modulating
the modulator might offer a tunable regulation of LRRK2 kinase activity. To achieve this, we will need
to understand the biochemical and structural details of the Roc-COR domains. The bottleneck in these
endeavors has been obtaining sufficient amounts of correctly folded proteins suitable for the biochemical
and biophysical studies. Even so, there are ongoing efforts to achieve precisely that.
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Abbreviations
GEFs Guanine nucleotide exchange factors
GAPs GTPase-activating proteins
Roc Ras of complex proteins
GbpC cGMP binding protein C
LRR Leucine-rich repeat
COR C-terminal of Roc
LRRK1/2 Leucine-rich repeat kinase 1/2
MASL1 Malignant fibrous histiocytoma amplified sequence 1 (MFHAS1)
DAPK1 Death-associated protein kinase 1
GRAM Glucosyltransferases Rab-like GTPase activators and Myotubularins
PD Parkinson’s disease
AD Alzheimer’s disease
OSMD Osteosclerotic metaphyseal dysplasia
CMA Chaperone-mediated autophagy
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GADs G-proteins activated by nucleotide-dependent dimerization
CK1 Casein kinase 1 alpha
PP1 Protein phosphatase 1
PP2A Protein phosphatase 2A
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